Basimglurant

Drug Profile

Basimglurant

Alternative Names: RG-7090; RO-4917523

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidepressants; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Discontinued Fragile X syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in France (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Netherlands (PO, Capsule)
  • 17 Aug 2015 Phase-II development for treatment-resistant depression is ongoing in US, EU, Japan, Chile, Mexico, Russia and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top